ACXP
Acurx Pharmaceuticals, Inc.
There isn't enough reported data to score ACXP yet.
ACXP Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ACXP's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
ACXP PE Valuation
ACXP has no meaningful PE right now: it lost money over the past year.
ACXP Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| High |
Analysts expect ACXP's losses to shrink, with revenue holding steady.
ACXP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.73 | +$4.79 |
| Q2 2026 | -$4.47 | +$6.22 |
| Q1 2026 | -$5.83 | +$8.17 |
| Q4 2025 | -$7.41 | +$9.99 |
| Q3 2025 | -$8.52 | +$13.28 |
| Q2 2025 | -$10.69 | +$12.51 |
| Q1 2025 | -$14.00 | +$9.60 |
| Q4 2024 | -$17.40 | +$5.60 |
ACXP is still losing money, but far less than before: $3.73 per share over the past year, against $30.99 at its worst in early 2022.
ACXP Quarterly Revenue
ACXP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.5M | -$607.3K |
| Q2 2026 | -$1.7M | -$39.4K |
| Q1 2026 | -$1.4M | +$644K |
| Q4 2025 | -$1.2M | +$1.1M |
| Q3 2025 | -$1.9M | +$308.9K |
| Q2 2025 | -$1.7M | +$1.2M |
| Q1 2025 | -$2.1M | +$1M |
| Q4 2024 | -$2.3M | +$1.9M |
ACXP has burned cash in almost every quarter: −$7M over the past year, against −$8M the year before.
ACXP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +25% | +1.1M shares |
| 1 year | +347% | +4.1M shares |
| 3 years | +813% | +4.7M shares |
| 5 years | +1014% | +4.8M shares |
| Available history | +1014% | +4.8M shares |
ACXP has 5M diluted shares, up 347% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ACXP Net Leverage
ACXP's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ACXP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.1 | Neutral |
| Stochastic | 6.1 | Oversold |
ACXP's weekly RSI is 33 (neutral) and its Stochastic is 6 (oversold).
ACXP PE vs Healthcare Sector
ACXP has no meaningful PE right now: it lost money over the past year.
ACXP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.15 | 15% below |
| 20 week MA | $1.34 | 27% below |
| 50 week MA | $2.06 | 52% below |
| 100 week MA | $5.43 | 82% below |
| 200 week MA | $29.5 | 97% below |
ACXP is in a downtrend: it's below all five of its weekly moving averages, and 97% below its 200-week average.
ACXP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $157.8 | $95.0 | -40% |
| 2022 | $95.0 | $78.6 | -17% |
| 2023 | $78.6 | $76.6 | -2.5% |
| 2024 | $76.6 | $17.9 | -77% |
| 2025 | $17.9 | $3.19 | -82% |
| 2026 YTD | $3.19 | $0.98 | -69% |
ACXP has finished every year since 2021 lower, and it's down 69% so far in 2026.